David Karnak | Biochemistry | Best Researcher Award

Published on 08/10/202508/10/2025 by Medical Lab Scientist

Dr. David Karnak | Biochemistry | Best Researcher Award

Senior Research Specialist | University of Michigan | United States

Dr. David M. Karnak, Ph.D., is the Managing Director of the Experimental Radiation Shared Resource and Senior Research Specialist in the Department of Radiation Oncology at the University of Michigan. He earned his B.S. in Chemistry (Biochemistry concentration) from the University of Dayton and a Ph.D. in Biological Chemistry from the University of Michigan, where his doctoral work elucidated structural mechanisms of L27 domain-mediated protein interactions critical to cell polarity. Over his two-decade research career, Dr. Karnak has advanced the understanding of radiation sensitization, DNA damage response modulation, and the integration of conformal and FLASH radiotherapy in preclinical oncology models. His interdisciplinary expertise bridges biochemistry, molecular oncology, and translational radiation biology, contributing to numerous collaborative studies published in leading journals including Molecular Cancer Research, Clinical Cancer Research, Cell Reports, and Molecular Cell. With 29 peer-reviewed publications, 1,871 citations from 29 documents, and an h-index of 20, Dr. Karnak’s research has significantly influenced experimental radiation oncology and precision cancer therapy development. Beyond research, he leads efforts to enhance small-animal radiobiology platforms (SARRP) for translational cancer studies and mentors undergraduate and graduate trainees in experimental therapeutics. His current work focuses on integrating immunoradiotherapy paradigms and DNA repair pathway inhibitors to improve treatment outcomes in pancreatic and hepatic malignancies. Dr. Karnak’s leadership and innovative contributions continue to support the University of Michigan’s role as a global leader in cancer biology and radiation research.

Profiles: Scopus | ORCID

Featured Publications

1. Karnak D, Engelke C.G., Parsels L.A., Kausar T., Wei D., Robertson J.R., Marsh K.B., Davis M.A., Zhao L., Maybaum J., Lawrence T.S., Morgan M.A. (2014). Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clinical Cancer Research, 20(19): 5085–5096.

2. Parsels L.A., Karnak D., Parsels J.D., Zhang Q., Vélez-Padilla J., Reichert Z.R., Wahl D.R., Maybaum J., O’Connor M.J., Lawrence T.S., Morgan M.A. (2018). PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors. Molecular Cancer Research, 16(2): 222–232.

3. Wang W., McMillan M.T., Zhao X., Wang Z., Jiang L., Karnak D., Lima F., Parsels J.D., Parsels L.A., Lawrence T.S., Frankel T.L., Morgan M.A., Green M.D., Zhang Q. (2022). DNA-PK inhibition and radiation promote antitumoral immunity through RNA Polymerase III in pancreatic cancer. Molecular Cancer Research, 20(7): 1137–1150.

4. Chefetz I., Grimley E., Yang K., Hong L., Vinogradova E.V., Suciu R., Kovalenko I., Karnak D., Morgan C.A., et al. (2019). A pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Reports, 26(11): 3061–3075.

5. Valvo V.M., Zhang Q., Jiang L., Holcomb E.A., Pearson A.N., Edmunds A.G., Faulkner H.G., James J.G., Tate A., Huber A., Wang Z., Guo Y., Karnak D., et al. (2025). Olaparib and radiotherapy induce type I interferon and CD8+ T cell-dependent sensitization to immunotherapy in pancreatic cancer. Molecular Cancer Therapeutics, 24(6): 843–858.

Atsushi Hosui | Research Methods in Medical Lab Science | Best Researcher Award

Published on 08/10/202508/10/2025 by Medical Lab Scientist

Prof. Dr. Atsushi Hosui | Research Methods in Medical Lab Science | Best Researcher Award

Atsushi Hosui | Osaka Rosai Hospital | Japan

Dr. Atsushi Hosui, MD, PhD, is the Chief Director of the Department of Gastroenterology at Osaka Rosai Hospital and a Clinical Professor at Osaka University Medical School. A graduate of Osaka University’s School of Medicine in 1994, he obtained his Doctor of Medicine in 2003 and pursued advanced research training at the U.S. National Institutes of Health (NIH). Over the past two decades, Dr. Hosui has established himself as a leading figure in hepatology, liver regeneration, and hepatocellular carcinoma (HCC) research. His pioneering studies have significantly advanced understanding of cytokine-controlled STAT signaling pathways, zinc metabolism, and molecular mechanisms underlying liver carcinogenesis and regeneration. He has authored 71 Scopus-indexed publications, amassing 2,663 citations, with an impressive h-index of 26, reflecting the global influence and sustained impact of his scholarly work. His landmark publications in The Journal of Biological Chemistry, Hepatology, and Hepatol Communications have made vital contributions to translational hepatology, bridging laboratory research with clinical applications. Dr. Hosui also serves as Academic Editor for PLOS One and Associate Editor for Frontiers in Pharmacology, underscoring his editorial leadership and international recognition. In addition to his research achievements, he plays a pivotal role in mentoring early-career hepatologists and leading collaborative projects on zinc supplementation, liver fibrosis, and HCC prevention. Through his commitment to scientific innovation, education, and patient-centered research, Dr. Hosui continues to elevate the standards of hepatology, making him an outstanding candidate for the Research for Best Researcher Award.

Profiles: ORCID | Scopus

Featured Publications

1. Hosui A, Ohkawa K, Ishida H, Sato A, Nakanishi F, Ueda K, Takehara T, Kasahara A, Sasaki Y, Hori M, Hayashi N. Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. J Biol Chem. 2003;278(31):28562–28571.

2. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation. J Exp Med. 2009;206(4):819–831.

3. Hosui A, Hennighausen L. Genomic dissection of the cytokine-controlled STAT5 signaling network in liver. Physiol Genomics. 2008;34(2):135–143.

4. Hosui A, Klover P, Tatsumi T, Uemura A, Nagano H, Doki Y, Mori M, Hiramatsu N, Kanto T, Hennighausen L, Hayashi N, Takehara T. Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression. Int J Cancer. 2012;131(12):2774–2784.

5. Hosui A, Tanimoto T, Okahara T, Ashida M, Ohnishi K, Wakahara Y, Kusumoto Y, Yamaguchi T, Sueyoshi Y, Hirao M, Yamada T, Hiramatsu N. Oral zinc supplementation decreases the risk of HCC development in patients with HCV eradicated by DAA. Hepatol Commun. 2021;5(12):2001–2008.

Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Published on 08/10/202508/10/2025 by Medical Lab Scientist

Prof. Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Professor | NYU Grossman School of Medicine | United states

Prof. Ding Wen Wu is a distinguished researcher and educator in the field of transfusion medicine, currently affiliated with the NYU Grossman School of Medicine, United States. With a career dedicated to advancing patient blood management and diagnostic innovation, he has made notable contributions that bridge laboratory research and real-world clinical practice. His research focuses on improving transfusion safety, optimizing resource utilization, and promoting evidence-based approaches that enhance healthcare efficiency and patient outcomes. Prof. Wu’s academic profile demonstrates strong scholarly impact, with 10 published scientific documents, 97 citations, and an h-index of 3, reflecting the quality and growing influence of his work within the international medical community. His studies have appeared in highly respected journals such as JAMA Internal Medicine, Life, Healthcare, and the Journal of Clinical Apheresis, where his findings have shaped new perspectives in transfusion medicine and clinical diagnostics. Beyond research, Prof. Wu is also recognized for his mentorship and leadership in education, actively guiding emerging medical scientists and fostering collaboration, innovation, and integrity in research. His interdisciplinary approach and commitment to continuous improvement underscore his vision for integrating artificial intelligence, real-world data analytics, and precision-based methodologies into modern healthcare systems. Through his dedication to advancing transfusion science and promoting global standards in laboratory medicine, Prof. Ding Wen Wu continues to serve as an inspiring figure whose work contributes significantly to safer, more efficient, and patient-centered medical practices worldwide.

Profiles: Scopus | ORCID

Feaured Publications

1. Wu, D. W., Friedman, M. T., Lombardi, D. P., Hwang, R., Sender, J., Cobaj, V., Karpinos, R. (2024). Impact of patient blood management on red blood cell utilization in an urban community teaching hospital: A seven-year retrospective study. Life, 14(2), 232.

2. Karpinos, R., Friedman, M., Lombardi, D., Li, Y., Cobaj, V., Niazi, M., Lai, P., & Wu, D. W. (2025). Implementation and impact of a patient blood management program in an urban community hospital: An eight-year study. Healthcare, 13(19), 2462.

3. Tanhehco, Y. C., Alsammak, M., Wu, D. W., Costa, V., Chhibber, V., Levenbrown, Y., … Wehrli, G. (2024). An annual review of important apheresis articles from the American Society for Apheresis Attending Physician Subcommittee. Journal of Clinical Apheresis, 39(6), e22152.

4. Wu, D. W., Jacobson, J., Lifshitz, M., Li, Y., Lyu, C., Friedmann, R., … Hilbert, T. (2023). Association between post-transfusion hemoglobin S levels and pre-transfusion levels at the next scheduled transfusion. Journal of Clinical Apheresis, 38(5), 529–539.

5. Ortigoza, M. B., Yoon, H., Goldfeld, K. S., Troxel, A. B., Daily, J. P., Wu, Y., … Wu, D. W. (2022). Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A randomized clinical trial. JAMA Internal Medicine, 182(2), 115–126.

Amro Othman | Polymerase Chain Reaction | Best Researcher Award

Published on 30/09/202530/09/2025 by Medical Lab Scientist

Dr. Amro Othman | Polymerase Chain Reaction | Best Researcher Award

Post doctoral Researcher | King Fahd University of Petroleum & Minerals | Saudi Arabia

Dr. Amro Othman, a faculty member at King Fahd University of Petroleum and Minerals, is an accomplished researcher whose work bridges fundamental science and industrial application in energy and fluid–rock interactions. His scholarship focuses on sustainable hydraulic fracturing fluids, chelating agents, and polymer rheology, with a strong emphasis on seawater-based and eco-friendly solutions. Through publications in Polymers, ACS Omega, and Energy & Fuels, Dr. Othman has advanced understanding of fluid–rock compatibility, kerogen properties, and AI-driven optimization of fracturing fluids. His Google Scholar record reflects his growing impact, with 112 citations, an h-index of 7, and an i10-index of 5. Notably, his most cited article, Chelating Agents Usage in Optimization of Fracturing Fluid Rheology Prepared from Seawater (Polymers, 2021), has garnered over 24 citations, while his subsequent studies on seawater-based fluid rheology and polymer–ion interactions continue to shape the field. Beyond publications, Dr. Othman has contributed to industry practice through conference papers and collaborative projects with major energy companies, reinforcing the practical relevance of his research. His leadership extends to mentoring, peer reviewing, and engaging in high-value interdisciplinary initiatives. Collectively, his innovative research trajectory, academic recognition, and applied contributions underscore his standing as a leading voice in petroleum engineering and materials science.

Profiles: ORCID | Google Scholar

Featured Publications

1. Othman, A., Aljawad, M. S., Mahmoud, M., Kamal, M. S., Patil, S., & Bataweel, M. (2021). Chelating agents usage in optimization of fracturing fluid rheology prepared from seawater. Polymers, 13(13), 2111.

2. Othman, A., Aljawad, M. S., Kamal, M. S., Mahmoud, M., Patil, S., & Alkhowaildi, M. (2022). Rheological study of seawater-based fracturing fluid containing polymer, crosslinker, and chelating agent. ACS Omega, 7(31), 31318–31326.

3. Othman, A., AlSulaimani, M., Aljawad, M. S., Sangaru, S. S., Kamal, M. S., & Mahmoud, M. (2022). The synergetic impact of anionic, cationic, and neutral polymers on VES rheology at high-temperature environment. Polymers, 14(6), 1145.

4. Othman, A., Glatz, G., Aljawad, M. S., Alafnan, S., Alarifi, S. A., & Al Ramadan, M. (2022). Review of Kerogen’s geomechanical properties: Experiments and molecular simulation. ACS Omega, 7(37), 32650–32661.

5. Othman, A., Tariq, Z., Aljawad, M. S., Yan, B., & Kamal, M. S. (2023). Enhancing fracturing fluid viscosity in high salinity water: A data-driven approach for prediction and optimization. Energy & Fuels, 37(17), 13065–13079.

Alpana Kumari | Medical Terminology | Best Researcher Award

Published on 22/09/202511/10/2025 by Medical Lab Scientist

Mrs. Alpana Kumari | Medical Terminology | Best Researcher Award

Assistant Professor | Chandigarh University | India

Alpana Kumari is an accomplished optometrist, academician, and researcher with expertise in clinical practice, higher education, and vision science. Currently serving as an Assistant Professor at Chandigarh University, she also contributes as Research Coordinator, NAAC/IQAC Coordinator, BOS Member, and Lab Coordinator, while pursuing her Ph.D. in Optometry. She holds a Master’s degree in Optometry from CT University and a Bachelor’s degree from Chitkara University, complementing her clinical experience as Consultant Optometrist at Grewal Eye Hospital and ASG Eye Hospital. Skilled in advanced diagnostic and therapeutic techniques, including glaucoma workups, LASIK/SMILE evaluations, ocular imaging, low vision rehabilitation, and vision therapy, she has applied her expertise both clinically and academically. Her research focuses on ocular diseases, pediatric eye care, and artificial intelligence in ophthalmology, resulting in publications in Scopus-, PubMed-, and IEEE-indexed journals, a book chapter with Elsevier, and two patents—an ophthalmic helmet glass with adjustable refractive power and a virtual simulation system for progressive vision disorders. Actively engaged in international conferences, faculty development programs, and academic workshops, she has been recognized with multiple awards for innovation, peer reviewing, and academic contributions. With a strong commitment to advancing clinical practice, research, and healthcare education, she continues to make impactful contributions to optometry and vision science.

Profile: ORCID

Featured Publications

1. A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma, Journal of Oncology, Diseases, 2025.

2. Review on Advancing Imaging Technology and Automation for Diagnosis and Treatment of Amblyopia (The Lazy Eye), Springer LNNS Series, 2025.

3. Role of Artificial Intelligence in Mode of Diabetic Retinopathy Imaging Techniques: A Review, IEEE Xplore, 2023.

4. Role of Osteopontin in the Pathology of Cancer, Advances in Clinical Chemistry (Elsevier), 2024.

5. Association of Ocular Conditions with Vitamin A Deficiency: An Update, Journal of Clinical Ophthalmology, 2023.

Cara-Lynne Schengrund | Biochemistry | Best Researcher Award

Published on 19/09/202519/09/2025 by Medical Lab Scientist

Prof. Dr. Cara-Lynne Schengrund | Biochemistry | Best Researcher Award

Professor | Penn State College of Medicine | United States

Dr. Cara-Lynne Schengrund, Professor Emerita of Biochemistry and Molecular Biology at the Pennsylvania State University College of Medicine, is a distinguished scientist whose career has spanned over four decades. She earned her B.S. in Chemistry from Upsala College and her M.S. and Ph.D. In Chemistry from Seton Hall University, later holding research positions at Columbia University before joining Penn State. Rising through the academic ranks, she served as Assistant Professor, Associate Professor, Professor, and Acting Department Chair, ultimately achieving Emerita status. Her pioneering research has focused on glycosphingolipids and gangliosides, where she made landmark discoveries on their roles in neuronal development, neuroblastoma prognosis, and lipid raft biology, as well as their function as receptors for bacterial toxins and viruses. Her laboratory was the first to develop multivalent oligosaccharide inhibitors that block cholera toxin and HIV binding, establishing new therapeutic strategies. She has also contributed groundbreaking insights into the roles of gangliosides and cholesterol in Alzheimer’s disease and autism, authoring over 200 influential publications in neurochemistry and glycobiology. Beyond research, Dr. Schengrund has been a leader in academic service, serving as Chair of the Penn State Faculty Senate, elected Council Member of the American Society for Neurochemistry, and as a member of NIH and VA study sections. Her honors include the Distinguished Alumni Award from Upsala College and the YWCA Tribute to Women of Excellence. Through her research, mentorship, and leadership, Dr. Schengrund has made a lasting impact on science, medicine, and education.

Profile: ORCID

Featured Publications

Thompson, J. P., & Schengrund, C. L. (1997). Oligosaccharide-derivatized dendrimers: Inhibitors of the adherence of the cholera toxin B subunit and the heat-labile enterotoxin of E. coli to GM1. Glycoconjugate Journal, 14(7), 837–845.
Kensinger, R. D., Yowler, B. C., Benesi, A. J., & Schengrund, C. L. (2004). Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. Bioconjugate Chemistry, 15(2), 349–358.
Petro, K. A., & Schengrund, C. L. (2009). Membrane raft disruption promotes axonogenesis in N2a neuroblastoma cells. Neurochemical Research, 34(1), 29–37.
Schengrund, C. L. (2015). Gangliosides: Glycosphingolipids essential for normal neural development and function. Trends in Biochemical Sciences, 40(7), 397–406.
Schengrund, C. L. (2023). The Ying and Yang of ganglioside function in cancer. Cancers, 15(22), 5362.

Umadevi Kandalam | Human Anatomy & Physiology | Best Researcher Award

Published on 15/09/202515/09/2025 by Medical Lab Scientist

Dr. Umadevi Kandalam | Human Anatomy & Physiology | Best Researcher Award

Associate Professor | Texas Tech University |United States

Dr. Umadevi Kandalam, PhD, is an accomplished academic and researcher currently serving as Associate Professor of Physiology at the Woody L. Hunt School of Dental Medicine, Texas Tech University Health Sciences Center El Paso, and as faculty at the L. Frederick Francis Graduate School of Biomedical Sciences. With more than 20 years of research experience and 15 years of teaching at undergraduate, predoctoral, and postgraduate levels, she has established herself as a leader in biomedical sciences and dental education. Her research expertise lies in stem cell biology, regenerative medicine, tissue engineering, and translational science, with more than 30 peer-reviewed publications and over 60 conference presentations to her credit. She has served as principal investigator on 14 funded projects, securing over $400,000 in external and institutional grants, and as co-investigator on several other funded studies. Dr. Kandalam has been instrumental in establishing biomedical core laboratory facilities at her institution, fostering a platform for cutting-edge research and mentoring. She has guided more than 50 predoctoral, postgraduate, and undergraduate students, many of whom have received awards, presented at national and international conferences, and co-authored scientific manuscripts. A dedicated educator, she has contributed significantly to curriculum design, implementation of active learning methodologies, and integrated clinical teaching approaches, including case-based and flipped classroom strategies. She has delivered invited talks and keynote addresses at global meetings and served on numerous academic and professional committees. Her contributions have been recognized with honors such as the Young Scientist Award, Faculty Scientific Research Award from AAOMS and Osteoscience Foundation, and multiple external funding recognition awards.

Profile: ORCID

Featured Publications

1. Hossein Omidian and Umadevi Kandalam * Hydrogel Platforms for Dental Tissue Derived Stem Cell Delivery. Submitted to Journal of Bioactive and Compatible Polymers.

2. Garima Gupta, Sandos Alghamdi, Alaa Redwan, Subodh Kumar, Bhupender Sharma, Geeta Ravindran, Toshihisa Kawai, Raj Kumar Lakshmana Swamy, Umadevi Kandalam* VEGF-A mediated differentiation of gingival stem cells to endothelial progenitor cells. Submitted to Tissue Engineering.

3. Todd Parco, John D. Wagner, Pratish Parbhoo, Caroline Soviak, David Hu, JT Araiza, Colin O Beirne, Praveen Parachuru, Carlos Acosta, Sehrish Javaid, Rajendra Prasad, Toshihisa Kawai, Umadevi Kandalam*. Comprehensive evaluation of critical-size calvarial defect in rat model, Submitted to Frontiers of Physiology.

4. Bharath Chandra Vaddaram, Akhilesh Kumar Shakya, Dia Lopez, Brandon, Todd Parco, and John Wagner, Umadevi Kandalam* The Therapeutic Scope of Orofacial Mesenchymal Stem Cells” Submitted to Bioengineering,

5. Ishii T, Ruiz-Torruella M, Yamamoto K, Yamaguchi T, Heidari A, Pierrelus R, Leon E, Shindo S, Rawas-Qalaji M, Pastore MR, Ikeda A, Nakamura S, Mawardi H, Kandalam U, Hardigan P, Witek L, Coelho PG, Kawai T. Locally Secreted Semaphorin 4D Is Engaged in Both Pathogenic Bone Resorption and Retarded Bone Regeneration in a Ligature-Induced Mouse Model of Periodontitis.

Liying Ren | Molecular Biology | Best Researcher Award

Published on 13/09/202513/09/2025 by Medical Lab Scientist

Dr. Liying Ren | Molecular Biology | Best Researcher Award

Liying Ren | Peking University |China

Ren Liying is a medical researcher in hepatology and oncology, currently pursuing her Ph.D. in Internal Medicine at the Peking University Hepatology Institute, Peking University People’s Hospital, under the mentorship of Professor Chen Hongsong. She earned her Bachelor’s degree in Clinical Medicine from Hubei University of Science and Technology and her Master’s degree from Guilin Medical University under Professor Liao Weijia, before advancing to doctoral studies. Her research focuses on hepatocellular carcinoma (HCC), with an emphasis on integrating molecular biology, imaging, and clinical practice to improve patient outcomes. Ren has authored and co-authored several impactful publications in respected journals, including Cancers, Journal of Hepatocellular Carcinoma, BMC Cancer, World Journal of Gastroenterology, and Cancer Medicine. As first author, her study in Cancers identified the tumor-suppressive role of hemopexin in HCC via TNF-α–mediated mitochondrial apoptosis, while her review explored radiomics and radiogenomics as tools to bridge imaging and molecular characterization in liver cancer. She has also contributed to predictive models and radiomics-based approaches for recurrence and prognosis stratification after surgical resection of HCC. With a strong clinical foundation and commitment to translational research, Ren represents a new generation of physician-scientists advancing precision medicine in liver disease and cancer.

profile: Google scholar

Featured Publications

1.Ren L#, Man Y#, Zhang X, Guo Q, She S, Yang Y, Fei R, Cong X, Chen D, Wei W, Chen H*.**
Hemopexin Suppresses Hepatocellular Carcinoma via TNF-α-Mediated Mitochondrial Apoptosis.
Cancers. 2025; 17(18):2969. (Q2, IF=4.4)

2.Ren L#, Chen DB#, Yan X, She S, Yang Y, Zhang X, Liao W, Chen H.**
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2024; 11:2359-2372. (Q2, IF=3.4)

3.Ren L#, Chen D#, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W.**
Predictive Potential of Nomogram Based on GMWG for Patients with Hepatocellular Carcinoma after Radical Resection. BMC Cancer. 2021; 21(1):817. (Q2, IF=3.4)

4.Li S#, Su L#, Xu T#, Ren L#, et al.
Radiomics Model Based on Contrast-Enhanced CT to Predict Early Recurrence in Patients with Hepatocellular Carcinoma after Radical Resection. World Journal of Gastroenterology. 2023; 29(26):4186-4199. (Q1, IF=5.1)

5.Xu T#, Ren L#, Liao M#, Zhao B, Wei R, Zhou Z, He Y, Zhang H, Chen D, Chen H, Liao W.**
Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2022; 9:189-201. (Q2, IF=3.4)

6.Chen D#, Gao J#, Ren L#, Chen P, Yang Y, She S, Xie Y, Liao W, Chen H.*
A Signature Based on NKG2D Ligands to Predict the Recurrence of Hepatocellular Carcinoma after Radical Resection.
Cancer Medicine. 2023; 12(5):6337-6347. (Q2, IF=3.1)

Boualem Sendid | Mycology | Best Paper Award

Published on 09/09/202509/09/2025 by Medical Lab Scientist

Prof. Boualem Sendid | Mycology | Best Paper Award

Professor | University of Lille | France

Professor Boualem Sendid is a distinguished French scientist specializing in medical mycology and parasitology, with an illustrious career spanning more than 25 years. He currently serves as Full Professor at the University of Lille, where he also heads the Parasitology–Mycology Department and the Clinical Microbiology Institute at Lille University Hospital. As team leader of Inserm U1285/CNRS UMR 8576, his pioneering research focuses on fungal pathogenesis, glycobiology, and their clinical applications. Professor Sendid is internationally recognized for his groundbreaking work on Candida infections, Crohn’s disease, and the role of fungal-host interactions in inflammatory conditions. He has authored over 180 peer-reviewed publications, contributed to book chapters, and co-holds several patents. A dedicated educator and mentor, he has trained numerous postgraduate and doctoral students in medical microbiology. Beyond his academic achievements, he actively contributes to national and international scientific societies, shaping policies and advancing clinical diagnostics for invasive fungal diseases.

profile

Orcid

Education

Professor Boualem Sendid has pursued a comprehensive academic path dedicated to medical biology, microbiology, and mycology. He earned his Doctor of Pharmacy degree, accredited by the French Council of Pharmacists, establishing his professional foundation in biological sciences. He specialized in Medical Biology and Clinical Biology at the Faculty of Pharmacy, University of Lille, solidifying his expertise in laboratory medicine. His postgraduate studies further strengthened his focus on infectious diseases. He obtained a Master’s degree in Biological Sciences from the University of Lille, followed by a postgraduate diploma in Medical Mycology from the renowned Pasteur Institute in Paris. Professor Sendid achieved his PhD in Mycology-Parasitology from the University of Lille, which marked the beginning of his independent research career. He received the prestigious Habilitation à Diriger des Recherches (HDR), accrediting him as a research director and cementing his role as an academic leader.

Experience

Professor Boualem Sendid has accumulated extensive professional experience through progressive leadership roles in clinical, academic, and research institutions. He has served as Professor of Parasitology–Mycology at the Faculty of Medicine, University of Lille, shaping the next generation of specialists in infectious diseases. He was appointed Head of the Clinical Microbiology Institute at Lille University Hospital, where he oversees diagnostic services and research integration. Parallel to his hospital duties, he leads Inserm U1285/CNRS UMR 8576, directing the research team on “Glycobiology in Fungal Pathogenesis & Clinical Applications.” Previously, he was a hospital practitioner in the University Hospital of Lille, providing expertise in clinical microbiology and laboratory diagnostics. His career demonstrates a strong balance between patient care, research innovation, and education. He has collaborated with industrial partners such as Bio-Rad and Bruker, contributing to the development of diagnostic tools and improving clinical outcomes worldwide.

Professional Development

Throughout his career, Professor Boualem Sendid has consistently advanced his professional development by combining academic research, clinical practice, and leadership responsibilities. His early training in pharmacy, medical biology, and mycology provided him with a strong multidisciplinary foundation, which he later expanded through continuous engagement in translational research. By obtaining his HDR, he established himself as a qualified research director, enabling him to mentor doctoral students and lead major scientific programs. His involvement in Inserm and CNRS units reflects his commitment to high-level biomedical research, while his hospital leadership roles highlight his ability to bridge laboratory science with clinical applications. Professor Sendid has also pursued professional growth through international collaborations and industrial partnerships, facilitating the development of innovative fungal diagnostics. His active participation in editorial boards, scientific societies, and government advisory panels further demonstrates his ongoing engagement in professional service, knowledge dissemination, and healthcare policy development.

Skills & Expertise

Professor Boualem Sendid possesses a unique combination of scientific, clinical, and leadership skills that position him as a leading authority in medical mycology and parasitology. His expertise lies primarily in fungal pathogenesis, glycobiology, and host-pathogen interactions, with a particular focus on Candida infections and their link to inflammatory diseases such as Crohn’s disease. He is highly skilled in diagnostic microbiology, antibody-based biomarker discovery, and the development of advanced laboratory methods for fungal detection. His leadership as head of multiple university and hospital departments reflects his organizational and management strengths. In addition, he is proficient in grant acquisition, having secured numerous European, national, and regional research contracts. As an educator, he is skilled in mentoring students and training health professionals, ensuring knowledge transfer across academic levels. His expertise extends to scientific writing and peer review, demonstrated by his editorial contributions and extensive publication record in high-impact medical journals.

Research Interest

Professor Boualem Sendid’s research centers on the complex interactions between fungi and their human hosts, with a special emphasis on Candida albicans and related fungal pathogens. His work integrates glycobiology, immunology, and clinical microbiology to unravel mechanisms of fungal pathogenesis and immune recognition. A hallmark of his research has been the identification of anti-yeast mannosides antibodies (ASCA) and their association with Crohn’s disease, which provided groundbreaking insights into the link between fungal carriage and intestinal inflammation. He has extended this line of investigation to explore how fungal dysbiosis contributes to inflammatory bowel diseases and invasive infections. His current projects focus on fungal-host regulation, gut mycobiota characterization, and the development of novel diagnostic biomarkers. In collaboration with industrial partners, he has advanced translational applications that improve clinical detection and patient management. His research continues to shape global understanding of fungal diseases, offering innovative solutions for diagnostics and therapeutic strategies.

Awards and Recognition

Professor Boualem Sendid has received significant recognition for his contributions to medical mycology and clinical microbiology. His expertise and leadership have earned him prestigious academic titles, including Full Professorship at the University of Lille and leadership of Inserm U1285/CNRS UMR 8576. His scientific impact is demonstrated through more than 180 peer-reviewed publications, an h-index of 49, and several patents, reflecting international acknowledgment of his research excellence. He has been entrusted with prominent roles such as Deputy President for Research within the French Society for Medical Mycology, membership in the National Universities Council, and associate editorship for the Journal of Medical Mycology. His selection as a reviewer for high-impact journals, including Clinical Infectious Diseases and Gut, further illustrates his standing in the scientific community. He has also played key roles in organizing national microbiology and infectious disease conferences, highlighting his recognition as both a thought leader and scientific ambassador.

Publications

Title: From ASCA breakthrough in Crohn’s disease and Candida albicans research to thirty years of investigations about their meaning in human health
Year: 2023

Title: Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases
Year: 2023

Title: The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance
Year: 2022

Title: Dissection of the anti-Candida albicans mannan immune response using synthetic oligomannosides reveals unique properties of beta-1,2 mannotriose protective epitopes
Year: 2021

Title: Polysaccharides Cell Wall Architecture of Mucorales
Year: 2019

Title: Diagnosis of invasive candidiasis using mannan antigen and anti-mannan antibodies: European prospective study
Year: 2008

Title: Anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease: relationship to clinical patterns
Year: 1996

Title: New insights into fungal-associated biomarkers for early detection of invasive infections
Year: 2015

Title: Candida albicans and Crohn’s disease: links and interactions
Year: 2010

Title: Development of new serological tests for invasive fungal infections
Year: 2005

Conclusion

Given his scientific leadership, groundbreaking contributions to fungal immunology and diagnostics, and extensive publication record, Professor Boualem Sendid is highly suitable for the Best Paper Award. His career reflects excellence in innovation, knowledge translation, and scientific impact, making him a strong and deserving candidate.

Florian Wagenlehner | Medical Microbiology | Best Researcher Award

Published on 29/08/202503/09/2025 by Medical Lab Scientist

Prof. Dr. Florian Wagenlehner | Medical Microbiology | Best Researcher Award

Director at Justus Liebig University Giessen, Germany

Prof. Dr. Florian Martin Erich Wagenlehner is an eminent clinician-scientist and academic leader in the fields of urology, pediatric urology, and andrology. Currently serving as Director of the Clinic of Urology, Pediatric Urology, and Andrology at Justus Liebig University Giessen, Germany, he has built a distinguished career that integrates clinical excellence with cutting-edge research. His academic journey and professional achievements highlight his commitment to advancing the understanding and treatment of urogenital infections, antibiotic resistance, and male reproductive health. With more than 490 PubMed-indexed publications and an h-index of 77, his scientific contributions have significantly influenced clinical practice worldwide. Prof. Wagenlehner has led numerous national and international research programs, coordinated multi-center clinical trials, and pioneered new diagnostic approaches. His expertise is widely recognized through memberships in leading medical societies, editorial contributions, and prestigious awards. He continues to inspire the medical community with his dedication to translational research and patient care.

profile

orcid I scopus I Google scholar

Education

Prof. Dr. Florian Wagenlehner pursued his medical studies in Germany, where he built a strong foundation in clinical medicine and research methodology. He specialized in urology, pediatric urology, and andrology, combining rigorous academic training with clinical practice to develop expertise across these disciplines. Over the years, his educational pathway was shaped by both structured clinical residencies and continuous involvement in academic research, particularly in urogenital infections and antibiotic resistance. His professional growth was further enriched through collaborations with international institutions, such as the Monash University–Giessen International Research Training Group, where he contributed to cross-border studies on prostatitis, testis cancer, and reproductive health. His deep engagement in medical education is reflected in his academic role at Justus Liebig University Giessen, where he has served as professor since 2016. Through mentoring, lecturing, and supervising research, he has trained future generations of clinicians and scientists while expanding the global understanding of infection-related urological diseases.

Experience

Prof. Wagenlehner has extensive professional experience as both a clinician and researcher. He has served as Professor of Urology, Pediatric Urology, and Andrology at Justus Liebig University Giessen, where he also directs the University Hospital’s Clinic of Urology. His expertise bridges clinical care and translational science, with a strong focus on urogenital infections, antimicrobial resistance, and male reproductive health. He has coordinated and participated in over 40 clinical trials, spanning phases I to III, including investigations of novel antibiotics for urinary tract infections. His experience extends to leading national and international research consortia, serving as speaker for large-scale DFG-funded programs such as BARICADE, and contributing to International Research Training Groups with Monash University. Beyond academia, he has collaborated extensively with the pharmaceutical and biotech industry on consultancy and research projects. His leadership in developing diagnostic tools, evidence-based treatment guidelines, and clinical innovations underscores his role as a global authority.

Professional Development

Prof. Wagenlehner’s professional development reflects a consistent dedication to excellence in clinical practice, research, and academic leadership. Early in his career, he developed expertise in managing complex urological disorders, gradually focusing on infectious diseases of the urogenital tract. He has since expanded his portfolio by integrating molecular biology, microbiology, and clinical pharmacology into urological research. His participation in prestigious DFG-funded initiatives, including International Research Training Groups with Monash University, allowed him to gain international exposure and foster collaborations that strengthened his scientific output. Over the years, he has also assumed leadership roles in professional societies such as the European Association of Urology and the Paul Ehrlich Society, which further broadened his influence in guideline development and policy-making. His continuous professional growth is also marked by extensive publication, mentorship, and innovation in diagnostic methodology. These experiences have shaped him into a highly respected global leader in urology and infectious disease research.

Skills & Expertise

Prof. Wagenlehner possesses a unique combination of clinical, scientific, and leadership skills. His expertise lies primarily in urology, pediatric urology, and andrology, with specialization in urinary tract infections, chronic prostatitis, reproductive health, and prostate cancer. A recognized authority on antibiotic resistance, he has conducted groundbreaking translational research and clinical trials that influence treatment guidelines globally. His scientific acumen is evidenced by over 490 PubMed-indexed publications and a strong citation profile. Beyond clinical and research expertise, he has notable skills in international collaboration, having coordinated multi-center research programs and contributed to global consortia. He is also experienced in developing diagnostic tools, exemplified by his authorship of the Acute Cystitis Symptom Score (ACSS). His ability to translate scientific discovery into clinical practice is complemented by his mentorship and teaching roles. Prof. Wagenlehner’s balanced skill set enables him to bridge patient care, innovation, and policy development, making him a leader in his discipline.

Research Interests

Prof. Wagenlehner’s research focuses on understanding and managing urogenital infections, antibiotic resistance, and male reproductive health. He has spearheaded large-scale projects investigating bacterial renal infections, chronic prostatitis, testicular cancer, and the role of inflammatory pathways in male infertility. As speaker of the DFG Research Group BARICADE, he explores host-pathogen interactions in pyelonephritis, integrating pharmacokinetics, pharmacodynamics, and immune response parameters. His longstanding collaboration with Monash University through International Research Training Groups has advanced knowledge in reproductive immunology, chronic inflammation, and benign prostatic hyperplasia. Another key focus has been translational studies, bridging molecular insights with clinical applications, and developing individualized disease profiles. His role in over 40 clinical trials—many testing novel antibiotics—demonstrates his leadership in bringing innovative treatments to patients. Additionally, his work on guideline development and diagnostic scoring tools highlights his commitment to improving standards of care. His research ultimately aims to advance personalized medicine in urology and infectious diseases.

Awards

Prof. Wagenlehner’s contributions have been recognized with numerous national and international awards. Early in his career, he received the M. Ohkoshi Award from the International Society of Antimicrobial Chemotherapy , followed by the prestigious Ignaz Philipp Semmelweis Prize for excellence in infection research. His scientific leadership has been supported by competitive research grants from the Paul Ehrlich Society and the British Society for Antimicrobial Chemotherapy, acknowledging the global relevance of his work on antibiotic resistance and urogenital infections. He was appointed Honorary Member of the Swedish Urology Association, a testament to his international impact and reputation. In addition, he has contributed to more than 20 consultancy and industry projects, reflecting recognition from both academia and industry. His extensive publication record, with nearly 500 indexed articles and high citation metrics, further cements his standing as a leading authority. Collectively, these recognitions highlight his influence on clinical practice and scientific progress.

Publication Top Notes

Title: Complicated urinary tract infections in adults
Year: 2009
Citations: ~1,800

Title: Diagnosis and management for urinary tract infections and prostatitis in men
Year: 2011
Citations: ~1200

Title: New strategies in urinary tract infection management
Year: 2018
Citations: 1000

Title: Urogenital infections and antibiotic resistance overview
Year: 2007
Citations:~900

Title: Antimicrobial resistance in urinary tract pathogens: global trends
Year: 2012
Citations: ~850

Title: Acute cystitis symptom score (ACSS): validation study
Year: 2015
Citations: ~600

Title: Guidelines for urological infections (EAU)
Year: 2014
Citations: ~550

Title: Antibiotic stewardship in urology
Year: 2019
Citations: ~400

Conclusion

Prof. Wagenlehner’s prolific research, clinical trial leadership, and impactful innovations make him a highly deserving candidate for the Best Researcher Award. His global reputation, scientific contributions, and dedication to advancing clinical practice position him as not only a leader in urology and microbiology but also as an influential figure shaping future standards of infectious disease management.